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Alzheimer’s disease (AD) is highly heritable and recent studies have identified over 20 disease-86 
associated genomic loci. Yet these only explain a small proportion of the genetic variance, 87 
indicating that undiscovered loci remain. Here, we performed the largest genome-wide 88 
association study of clinically diagnosed AD and AD-by-proxy (71,880 cases, 383,378 controls). 89 
AD-by-proxy, based on parental diagnoses, showed strong genetic correlation with AD (rg=0.81). 90 
Meta-analysis identified 29 risk loci, implicating 215 potential causative genes. Associated genes 91 
are strongly expressed in immune-related tissues and cell types (spleen, liver and microglia). 92 
Gene-set analyses indicate biological mechanisms involved in lipid-related processes and 93 
degradation of amyloid precursor proteins. We show strong genetic correlations with multiple 94 
health-related outcomes, and Mendelian randomisation results suggest a protective effect of 95 
cognitive ability on AD risk. These results are a step forward in identifying the genetic factors that 96 






Alzheimer’s disease (AD) is the most frequent neurodegenerative disease with roughly 35 million 99 
people affected.1 AD is highly heritable, with estimates ranging between 60 and 80%.2 100 
Genetically, AD can be roughly divided into 2 subgroups: 1) familial early-onset cases that are 101 
often explained by rare variants with a strong effect,3 and 2) late-onset cases that are influenced 102 
by multiple common variants with low effect sizes.4 Segregation analyses have linked several 103 
genes to the first subgroup, including APP5, PSEN16 and PSEN27. The identification of these genes 104 
has resulted in valuable insights into a molecular mechanism with an important role in AD 105 
pathogenesis, the amyloidogenic pathway,8 exemplifying how gene discovery can add to 106 
biological understanding of disease aetiology.  107 
Besides the identification of a few rare genetic factors (e.g. TREM29 and ABCA710), 108 
genome-wide association studies (GWAS) have mostly discovered common risk variants for the 109 
more complex late-onset type of AD. APOE is the strongest genetic risk locus for late-onset AD, 110 
responsible for a 3- to 15-fold increase in risk.11 A total of 19 additional GWAS loci have been 111 
described using a discovery sample of 17,008 AD cases and 37,154 controls, followed by 112 
replication of the implicated loci with 8,572 AD patients and 11,312 controls.4 The currently 113 
confirmed AD risk loci explain only a fraction of the heritability of AD and increasing the sample 114 
size is likely to boost the power for detection of more common risk variants, which will aid in 115 
understanding biological mechanisms involved in the risk for AD.  116 
In the current study, we included 455,258 individuals (Nsum) of European ancestry, meta-117 
analysed in 3 phases (Figure 1). Phase 1 consisted of 24,087 clinically diagnosed late-onset AD 118 





individuals in the UK Biobank (UKB) for whom parental AD status was available (N proxy 120 
cases=47,793; N proxy controls=328,320). The value of by-proxy phenotypes for GWAS was 121 
recently demonstrated by Liu et al12 for 12 common diseases, including substantial gains in 122 
statistical power for AD. The high heritability of AD implies that case status for offspring can be 123 
partially inferred from parental case status and that offspring of AD parents are likely to have a 124 
higher genetic AD risk load. We thus defined individuals with one or two parents with AD as proxy 125 
cases, while upweighting cases with 2 parents. Similarly, the proxy controls include subjects with 126 
2 parents without AD, where older cognitively normal parents were upweighted to account for 127 
the higher likelihood that younger parents may still develop AD (see Methods). As the proxy 128 
phenotype is not a pure measure of an individual’s AD status and may include individuals that 129 
never develop AD, genetic effect sizes will be somewhat underestimated. However, the proxy 130 
case-control sample is very large, and therefore substantially increases power to detect genetic 131 
effects for AD12, as was also demonstrated in a more recent study using UKB13. Finally, in phase 132 
3, we meta-analysed all individuals of phase 1 and phase 2 together and tested for replication in 133 
an independent sample. 134 
 135 
Results 136 
Genome-wide meta-analysis for AD status 137 
Phase 1 involved a genome-wide meta-analysis for clinically-diagnosed AD case-control status 138 
using cohorts collected by 3 independent consortia (PGC-ALZ, IGAP and ADSP), totalling 79,145 139 
individuals (Nsum - effective sample size Neff=72,500) of European ancestry and 9,862,738 genetic 140 





encompassed whole exome sequencing data from 4,343 cases and 3,163 controls, while the 142 
remaining datasets consisted of genotype single nucleotide polymorphism (SNP) arrays. For PGC-143 
ALZ and ADSP, raw genotypic data were subjected to a standardized quality control pipeline. 144 
GWA analyses were run per cohort and then included in a meta-analysis alongside IGAP, for 145 
which only summary statistics were available (see Methods). As described in detail in the 146 
Supplementary Note, the phase 1 analysis identified 18 independent loci meeting genome-wide 147 
significance (GWS; P<5×10-8), all of which have been identified by previous GWAS (Table 1, 148 
Supplementary Figure 1, Supplementary Table 2). 149 
We next (phase 2) performed a GWAS using 376,113 individuals of European ancestry 150 
from UKB with parental AD status weighted by age to construct an AD-by-proxy status (Figure 1). 151 
Here, we identified 13 independent GWS loci, 8 of which overlapped with phase 1 (Table 1, 152 
Supplementary Note).  We observed a strong genetic correlation of 0.81 (SE=0.185) between AD 153 
status and AD-by-proxy, as well as substantial concordance in the individual SNP effects, as 154 
described in the Supplementary Note.  155 
Given the high genetic overlap, in phase 3 we conducted a meta-analysis of the clinical 156 
AD GWAS and the AD-by-proxy GWAS (Figure 1), comprising a total sample size of 455,258 157 
(Neff=450,734), including 71,880 (proxy) cases and 383,378 (proxy) controls. The linkage 158 
disequilibrium (LD) score intercept14 was 1.0018 (SE=0.0109) and the sample size-adjusted15  λ1000 159 
was 1.044, indicating that most of the inflation in genetic signal (λGC=1.0833) could be explained 160 
by polygenicity (Supplementary Figure 1B). There were 2,357 GWS variants, which were 161 
represented by 94 lead SNPs, located in 29 distinct loci (Table 1, Figure 2, Supplementary Figure 162 





as 9 loci that were sub-threshold in both individual analyses but reached significance in the meta-164 
analysis. A large proportion of the lead SNPs (60/94) was concentrated in the established APOE 165 
risk locus on chromosome 19. This region is known to have a complex LD structure and a very 166 
strong effect on AD risk, thus we consider these SNPs likely to represent a single association 167 
signal. Conditional analysis indicated that most loci represented a single fully independent signal, 168 
while the TREM2, PTK2B/CLU, and APOE loci contained multiple possible causal signals 169 
(Supplementary Note; Supplementary Tables 3-4).  170 
Of the 29 associated loci, 16 overlapped one of the 20 genomic regions previously 171 
identified by the GWAS of Lambert et al.,4 replicating their findings, while 13 were novel. The 172 
association signals of five loci (CR1, ZCWPW1, CLU/PTK2B, MS4A6a and APH1B) are partly based 173 
on the ADSP exome-sequencing data. Re-analysis of these loci excluding ADSP resulted in similar 174 
association signals (Supplementary Table 5), implying that we have correctly adjusted for partial 175 
sample overlap between IGAP and ADSP. The lead SNPs in three loci (with nearest genes HESX1, 176 
TREM2 and CNTNAP2) were only available in the UKB cohort (Table 1), but were of good quality 177 
(INFO>0.91, HWE P>.19, missingness<.003). These SNPs were all rare (MAF < .003), meaning that 178 
they will require future confirmation in another similarly large sample. However, variants in 179 
TREM2 have been robustly linked to AD in prior research9. 180 
Verifying the 13 novel loci against other recent  genetic studies on AD9,16,12,17,18, 4 loci 181 
(TREM2, ECHDC3, SCIMP and ABI3) have been previously discovered in addition to the 16 182 
identified by Lambert et al., leaving 9 novel loci at the time of this writing (ADAMTS4, HESX1, 183 
CLNK, CNTNAP2, ADAM10, APH1B, KAT8, ALPK2, AC074212.3). The ADAMTS4 and KAT8 loci have 184 





meta-analysis results with all loci of Lambert et al.4 to determine differences in associated loci, 186 
we were unable to observe 4 loci (MEF2C, NME8, CELF1 and FERMT2) at a GWS level (observed 187 
P-values were 1.6x10-5 to 0.0011), which was mostly caused by a lower association signal in the 188 
UKB dataset (Supplementary Table 6). By contrast, Lambert et al4 were unable to replicate the 189 
DSG2 and CD33 loci in the second stage of their study. In our study, DSG2 was also not supported 190 
(meta-analysis P=0.030; UKB analysis P=0.766), implying invalidation of this locus, while the CD33 191 
locus (rs3865444 in Table 1) was significantly associated with AD (meta-analysis P=6.34 x 10-9; 192 
UKB analysis P=4.97 x 10-5), implying a genuine genetic association with AD risk.  193 
Next, we aimed to find further support for the novel findings by using an independent 194 
Icelandic cohort (deCODE19,20), including 6,593 AD cases and 174,289 controls (Figure 1; 195 
Supplementary Table 7) to test replication of the lead SNP or an LD-proxy of the lead SNP (r2>.9) 196 
in each locus. We were unable to test two loci as the lead SNPs (and SNPs in high LD) either were 197 
not present in the Icelandic reference panel or were not imputed with sufficient quality. For 6 of 198 
the 7 novel loci tested for replication, we observed the same direction of effect in the deCODE 199 
cohort. Furthermore, 4 loci (CLNK, ADAM10, APH1B, AC074212.3) showed nominally significant 200 
association results (P<0.05) for the same SNP or a SNP in high LD (r2 > 0.9) within the same locus 201 
(two-tailed binomial test P=1.9x10-4). The locus on chromosome 1 (ADAMTS4) was very close to 202 
significance (P=0.053), implying stronger evidence for replication than for non-replication. Apart 203 
from the novel loci, we also observed sign concordance for 96.3% of the top (per-locus) lead SNPs 204 
in all loci from the meta-analysis (two-tailed binomial test P=4.17x10-7) that were available in 205 





As an additional method of testing for replication, we used genome-wide polygenic score 207 
prediction in two independent samples.21 The current results explain 7.1% of the variance in 208 
clinical AD at a low best fitting P-threshold of 1.69x10-5 in 761 individuals with case-control 209 
diagnoses (P=1.80x10-10). When excluding the APOE-locus (chr19: 45020859-45844508), the 210 
results explain 3.9% of the variance with a best fitting P-threshold of 3.5x10-5 (P=1.90x10-6). We 211 
also predict AD status in a sample of 1,459 pathologically confirmed cases and controls22 with an 212 
R2=0.41 and an area under the curve (AUC) of 0.827 (95% CI: 0.805-0.849, P=9.71x10-70) using the 213 
best-fitting model of SNPs with a GWAS P<.50, as well as R2=0.23 and AUC=0.733 (95% CI: 0.706-214 
0.758, P=1.16x10-45) using only APOE SNPs. This validation sample contains a small number of 215 
individuals overlapping with IGAP; previous simulations with this sample have indicated that this 216 
overfitting increases the margin of error of the estimate approximately 2-3%.22 This sample, 217 
however, represented severe, late-stage AD cases contrasted with supernormal controls, so the 218 
polygenic prediction may be higher than expected for typical case-control or population samples.  219 
 220 
Functional interpretation of genetic variants  221 
Functional annotation of all GWS SNPs (n=2,357) in the associated loci showed that SNPs were 222 
mostly located in intronic/intergenic areas, but also in regions that were enriched for chromatin 223 
states 4 and 5, implying effects on active transcription (Figure 3; Supplementary Table 8). 25 224 
GWS SNPs were exonic non-synonymous (ExNS) (Figure 3A; Supplementary Table 9) with likely 225 
deleterious impacts on gene function. Converging evidence of strong association (Z>|7|) and a 226 
high observed probability of a deleterious variant effect (CADD23 score≥30) was found for 227 





mutations are rare (MAF=0.002 and 0.001, respectively) and the alternative alleles were 229 
associated with higher risk for AD. The latter APOE missense mutation is the well-established 230 
protective allele Apoε2. Supplementary Tables 8 and 9 present a detailed annotation catalogue 231 
of variants in the associated genomic loci. We also applied a fine-mapping model24 to identify 232 
credible sets of causal SNPs from the identified GWS variants (Supplementary Table 8). The 233 
proportion of plausible causal SNPs varied drastically between loci; for example, 30 out of 854 234 
SNPs were selected in the APOE locus (#26), while 345 out of 434 SNPs were nominated in the 235 
HLA-DRB1 locus (#7). Credible causal SNPs were not limited to known functional categories such 236 
as ExNS, indicating more complicated causal pathways that merit investigation with the set of 237 
variants prioritized by these statistical and functional annotations.   238 
Partitioned heritability analysis,25 excluding SNPs with extremely large effect sizes (i.e. 239 
APOE variants) showed enrichment for h2SNP for variants located in H3K27ac marks 240 
(Enrichment=3.18, P=9.63×10-5), which are associated with activation of transcription, and in 241 
Super Enhancers (Enrichment=3.62, P=2.28×10-4), which are genomic regions where multiple 242 
epigenetic marks of active transcription are clustered (Figure 3D; Supplementary Table 10). 243 
Heritability was also enriched in variants on chromosome 17 (Enrichment=3.61, P=1.63x10-4) and 244 
we observed a trend of enrichment for heritability in common rather than rarer variants 245 
(Supplementary Figure 3; Supplementary Tables 11 and 12). Although a large proportion (23.9%) 246 
of the heritability can be explained by SNPs on chromosome 19, this enrichment is not significant, 247 
due to the large standard errors around this estimate (Supplementary Table 11). Overall these 248 





GWS SNPs are located in non-coding regions and are enriched for regions that have an activating 250 
effect on transcription. 251 
 252 
Implicated genes 253 
To link the associated variants to genes, we applied three gene-mapping strategies implemented 254 
in FUMA26 (see Methods). We used all SNPs with a P-value < 5x10-8 for gene-mapping. Positional 255 
gene-mapping aligned SNPs to 99 genes by their location within or immediately up/downstream 256 
(+/-10kb) of known gene boundaries, eQTL (expression quantitative trait loci) gene-mapping 257 
matched cis-eQTL SNPs to 168 genes whose expression levels they influence in one or more 258 
tissues, and chromatin interaction mapping linked SNPs to 21 genes based on three-dimensional 259 
DNA-DNA interactions between each SNP’s genomic region and nearby or distant genes, which 260 
we limited to include only interactions between annotated enhancer and promoter regions 261 
(Supplementary Figure 4; Supplementary Tables 13 and 14). This resulted in 192 uniquely 262 
mapped genes, 80 of which were implicated by at least two mapping strategies and 16 by all 3 263 
(Figure 4E).  264 
Of special interest is the locus on chromosome 8 (CLU/PTK2B). In the GWAS by Lambert 265 
et al.4, this locus was defined as 2 distinct loci (CLU and PTK2B). Although our conditional analysis 266 
based on genetic data also specified this locus as having at least 2 independent association signals 267 
(Supplementary Table 4), the chromatin interaction data in two immune-related tissues – the 268 
spleen and liver (Supplementary Table 14), suggests that the genomic regions indexed by PTK2B 269 
and CLU loci might physically interact (Figure 3E), therefore putatively affecting AD pathogenesis 270 





dissimilar between CLU and PTK2B, although both are expressed relatively highly in the brain and 272 
lymph nodes.27 Future studies should thus consider the joint effects of how these two genes 273 
simultaneously impact AD risk.  274 
Eight genes (HLA-DRB5, HLA-DRB1, HLA-DQA, HLA-DQB1, KAT8, PRSS36, ZNF232 and 275 
CEACAM19) are particularly notable as they are implicated via eQTL association in the 276 
hippocampus, a brain region highly affected early in AD pathogenesis (Supplementary Table 13). 277 
Chromosome 16 contains a locus implicated by long-range eQTL association (Figure 3F) clearly 278 
illustrating how the more distant genes C16orf93, RNF40 and ITGAX can be affected by a genetic 279 
factor (rs59735493) in various body tissues (e.g. blood, skin), including a change in expression for 280 
RNF40 observed in the dorsolateral prefrontal cortex. These observations emphasize the 281 
relevance of considering putative causal genes or regulatory elements not solely on the physical 282 
location but also on epigenetic influences. As detailed in the Supplementary Note, eQTLs were 283 
overrepresented in the risk loci and a number of QTL associations (including eQTLs, mQTLs and 284 
haQTLs) were identified in relevant brain regions, providing interesting targets for future 285 
functional follow-up and biological interpretation (Supplementary Tables 15-17).   286 
Although these gene-mapping strategies imply multiple putative causal genes per GWAS 287 
locus, several genes are of particular interest, as they have functional or previous genetic 288 
association with AD. For locus 1 in Supplementary Table 13, ADAMTS4 encodes a protein of the 289 
ADAMTS family which has a function in neuroplasticity and has been extensively studied for its 290 
role in AD pathogenesis.28 For locus 19, the obvious most likely causal gene is ADAM10, as this 291 
gene has been associated with AD by research focusing on rare coding variants in ADAM10.29 292 





supported by the putative causal molecular mechanism observed in dorsolateral prefrontal 294 
cortex eQTL and mQTL data (Supplementary Tables 15 and 16) for multiple common SNPs in LD. 295 
The lead SNP for locus 20 is a nonsynonymous variant in exon 1 of APH1B, which encodes for a 296 
protein subunit of the γ-secretase complex cleaving APP.30 A highly promising candidate gene for 297 
locus 21 is KAT8, as the lead SNP of this locus is located within the third intron of KAT8, and 298 
multiple significant variants within this locus influence the expression or methylation levels of 299 
KAT8 in multiple brain regions (Supplementary Tables 13 and 16) including hippocampus. The 300 
chromatin modifier KAT8 is regulated by KANSL1, a gene associated with AD in absence of APOE 301 
ɛ4. A study on Parkinson’s disease (PD) reported KAT8 as potential causal gene based on GWAS 302 
and differential gene expression results, implying a putative shared role in neurodegeneration of 303 
KAT8 in AD and PD.31 Although previously reported functional information on genes can be of 304 
great value, it is preferable to consider all implicated genes as putative causal factors to guide 305 
potential functional follow-up experiments.   306 
We next performed genome-wide gene-based association analysis (GWGAS) using 307 
MAGMA.32 This method annotates SNPs to known protein-coding genes to estimate aggregate 308 
associations based on all SNPs in a gene. It differs from FUMA as it provides a statistical gene-309 
based test, whereas FUMA maps individually significant SNPs to genes. With GWGAS, we 310 
identified 97 genes that were significantly associated with AD (Supplementary Figure 5; 311 
Supplementary Table 18), of which 74 were also mapped by FUMA (Figure 4E). In total, 16 genes 312 
were implicated by all four strategies (Supplementary Table 19), of which 7 genes (HLA-DRA, 313 
HLA-DRB1, PTK2B, CLU, MS4A3, SCIMP and RABEP1) are not located in the APOE-locus, and 314 






Gene-sets implicated in AD and AD-by-proxy 317 
Using the gene-based P-values, we performed gene-set analysis for curated biological pathways 318 
and tissue/single-cell expression. Four Gene Ontology (GO)33 gene-sets were significantly 319 
associated with AD risk: Protein lipid complex (P=3.93×10-10), Regulation of amyloid precursor 320 
protein catabolic process (P=8.16×10-9), High density lipoprotein particle (P=7.81x10-8), and 321 
Protein lipid complex assembly (P=7.96×10-7) (Figure 4A; Supplementary Tables 20 and 21). 322 
Conditional analysis on the APOE locus showed associations with AD for these four gene-sets to 323 
be independent of the effect of APOE, though part of the association signal was also attributable 324 
to APOE. All 25 genes of the High density lipoprotein particle pathway are also part of the Protein 325 
lipid complex; conditional analysis showed that these gene-sets are not interpretable as 326 
independent associations (P=0.18), but the other three sets are independently significant 327 
(Supplementary Table 20).  328 
Linking gene-based P-values to tissue- and cell-type-specific gene-sets, no association 329 
survived the stringent Bonferroni correction, which corrected for all tested gene-sets (i.e. 6,994 330 
GO categories, 53 tissues and 39 cell types). However, we did observe suggestive associations 331 
across immune-related tissues when correcting only for the number of tests within all tissue 332 
types or cell-types (Figure 4C; Supplementary Table 22), particularly whole blood (P=5.61×10-6), 333 
spleen (P=1.50x10-5) and lung (P=4.67x10-4), which were independent from the APOE-locus. In 334 
brain single-cell expression gene-set analyses, we found association for microglia in the mouse-335 
based expression dataset (P=1.96x10-3), though not surviving the stringent Bonferroni correction 336 





microglia in a second independent single-cell expression dataset in humans (P=2.56x10-3) 338 
(Supplementary Figure 6; Supplementary Table 24). As anticipated, both microglia signals are 339 
partly depending on APOE, though a large part is independent (Supplementary Tables 23 and 340 
24). 341 
 342 
Cross-trait genetic influences 343 
As described in the Supplementary Note and Supplementary Tables 25-26, we observed 344 
that the genetic influences on AD overlapped with a number of other diseases and psychological 345 
traits including cognitive ability and educational attainment, replicating previous studies.34,35 To 346 
extend these findings, we used Generalised Summary-statistic-based Mendelian 347 
Randomisation36 (GSMR) to test for potential credible causal associations of genetically 348 
correlated outcomes which may directly influence the risk for AD. Due to the nature of AD being 349 
a late-onset disorder and summary statistics for most other traits being obtained from younger 350 
samples, we do not report tests for the opposite direction of potential causality (i.e. we did not 351 
test for a causal effect of a late-onset disease on an early-onset disease). In this set of analyses, 352 
SNPs from the summary statistics of genetically correlated phenotypes were used as 353 
instrumental variables to estimate the putative causal effect of these “exposure” phenotypes on 354 
AD risk by comparing the ratio of SNPs’ associations with each exposure to their associations with 355 
AD outcome (see Methods). Association statistics were standardized, such that the reported 356 
effects reflect the expected difference in odds ratio (OR) for AD as a function of every SD increase 357 
in the exposure phenotype. We observed a protective effect of cognitive ability (OR=0.89, 95% 358 





and height (OR=0.96, 95%CI: 0.94-0.97, P=1.84x10-8) on risk for AD (Supplementary Table 27; 360 
Supplementary Figure 7). No substantial evidence of pleiotropy was observed between AD and 361 




By using an unconventional approach of including a proxy phenotype for AD to increase sample 366 
size, we have identified 9 novel loci and gained novel biological knowledge on AD aetiology. We 367 
were able to test 7 of the 9 novel loci for replication, of which 4 loci showed clear replication, 1 368 
locus showed marginal replication and 2 loci were not replicated at this moment. Both the high 369 
genetic correlation between the standard case-control status and the UKB by proxy phenotype 370 
(rg=0.81) and the high rate of novel loci replication in the independent deCODE cohort suggest 371 
that this strategy is robust. Through in silico functional follow-up analysis, and in line with 372 
previous research,18,37 we emphasise the crucial causal role of the immune system - rather than 373 
immune response as a consequence of disease pathology - by establishing variant enrichments 374 
for immune-related body tissues (whole blood, spleen, liver) and for the main immune cells of 375 
the brain (microglia). Of note, the enrichment observed for liver could alternatively indicate the 376 
genetic involvement of the lipid system in AD pathogenesis.38 Furthermore, we observe 377 
informative eQTL associations and chromatin interactions within immune-related tissues for the 378 
identified genomic risk loci. Together with the AD-associated genetic effects on lipid metabolism 379 
in our study, these biological implications (which are based on genetic signals and unbiased by 380 





between inflammation and lipids, as lipid changes might harm immune responses of microglia 382 
and astrocytes, and vascular health of the brain.39 383 
 In accordance with previous clinical research, our study suggests an important role for 384 
protective effects of several human traits on AD. Cognitive reserve has been proposed as a 385 
protective mechanism in which the brain aims to control brain damage with prior existing 386 
cognitive processing strategies.40 Our findings imply that some component of the genetic factors 387 
for AD might affect cognitive reserve, rather than being involved in AD-pathology-related 388 
damaging processes, influencing AD pathogenesis in an indirect way through cognitive reserve. 389 
Furthermore, a large-scale community-based study observed that AD incidence rates declined 390 
over decades, which was specific for individuals with at minimum a high school diploma.41 391 
Combined with our Mendelian randomisation results for educational attainment, this suggests 392 
that the protective effect of educational attainment on AD is influenced by genetics. Similarly, 393 
the observed positive effects of height could be a result of the genetic overlap between height 394 
and intracranial volume42,43, a measure associated to decreased risk of AD.44 This indirect 395 
association is furthermore supported by the observed increase in cognitive reserve for taller 396 
individuals.45 Alternatively, genetic variants influencing height might also affect biological 397 
mechanisms involved in AD aetiology, such as IGF1 that codes for the insulin-like growth factor 398 
and is associated with cerebral amyloid.46 399 
The results of this study could furthermore serve as a valuable resource for selection of 400 
promising genes for functional follow-up experiments and identify targets for drug development 401 





up experiments will result in a comprehensive understanding of late-onset AD aetiology, which 403 









UK Biobank: http://ukbiobank.ac.uk 413 
Database of Genotypes and Phenotypes (dbGaP): https://www.ncbi.nlm.nih.gov/gap 414 
Functional Mapping and Annotation (FUMA) software: http://fuma.ctglab.nl 415 
Multi-marker Analysis of GenoMic Annotation (MAGMA) software: 416 
http://ctg.cncr.nl/software/magma  417 
mvGWAMA and effective sample size calculation: https://github.com/Kyoko-wtnb/mvGWAMA 418 
LD Score Regression software: https://github.com/bulik/ldsc 419 
LD Hub (GWAS summary statistics): http://ldsc.broadinstitute.org/ 420 
LD scores: https://data.broadinstitute.org/alkesgroup/LDSCORE/ 421 






MSigDB curated gene-set database: 424 
http://software.broadinstitute.org/gsea/msigdb/collections.jsp 425 
NHGRI GWAS catalog: https://www.ebi.ac.uk/gwas/ 426 
Generalised Summary-data-based Mendelian Randomisation software: 427 
http://cnsgenomics.com/software/gsmr/ 428 
Credible SNP set analysis software: https://github.com/hailianghuang/FM-summary 429 
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Figure Legends 618 
Figure 1. Overview of analysis steps. The main genetic analysis encompasses the procedures to detect 619 
GWAS risk loci for AD. The functional analysis includes the in silico functional follow-up procedures with 620 
the aim to put the genetic findings in biological context. N = total of individuals within specified dataset. 621 
622 
623 
Figure 2. GWAS meta-analysis for AD risk (N=455,258). Manhattan plot displays all associations per 624 
variant ordered according to their genomic position on the x-axis and showing the strength of the 625 
association with the –log10 transformed P-values on the y-axis. The y-axis is limited to enable visualization 626 
of non-APOE loci. For the Phase III meta-analysis, the original –log10 P-value for the APOE locus is 276. 627 
628 
629 
Figure 3. Functional annotation of GWAS results. a) Functional effects of variants in genomic risk loci of 630 
the meta-analysis (the colours of the legend are ordered from right to left in the figure) – the second bar 631 
shows distribution for exonic variants only; b) Distribution of RegulomeDB score for variants in genomic 632 
risk loci, with a low score indicating a higher probability of having a regulatory function (see Methods); c) 633 
Distribution of minimum chromatin state across 127 tissue and cell types for variants in genomic risk loci, 634 
with lower states indicating higher accessibility (see Methods); d) Heritability enrichment of 28 functional 635 
variant annotations calculated with stratified LD score regression (bars represent standard errors). 636 
UTR=untranslated region; CTCF=CCCTC-binding factor; DHS=DNaseI Hypersensitive Site; 637 
TFBS=transcription factor binding site; DGF=DNAaseI digital genomic footprint; e) Zoomed-in circos plot 638 
of chromosome 8; f) Zoomed-in circos plot of chromosome 16. Circos plots show implicated genes by 639 
significant loci, where dark blue areas indicate genomic risk loci, green lines indicate eQTL associations 640 
and orange lines indicate chromatin interactions. Genes mapped by both eQTL and chromatin interactions 641 
are in red. The outer layer shows a Manhattan plot containing the negative log10-transformed P-value of 642 
each SNP in the GWAS meta-analysis of AD. Full circos plots of all autosomal chromosomes are provided 643 
in Supplementary Figure 4. 644 
645 
646 
Figure 4. Functional implications based on gene-set analysis, genetic correlations and functional 647 
annotations. The gene-set results are displayed per category of biological mechanisms (a), brain cell-types 648 
(b) and tissue types (c). The red horizontal line indicates the significance threshold corrected for all gene-649 
set tests of all categories, while the blue horizontal lines display the significance threshold corrected only 650 
for the number of tests within the three categories (i.e. gene-ontology, tissue expression or single cell 651 
expression); d) Genetic correlations between AD and other heritable traits (bars represent 95% 652 
confidence intervals); e) Venn diagram showing the number of genes mapped by four distinct strategies.653 
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Table 1. Summary statistics of significantly associated regions identified in the genome-wide association analysis of Alzheimer’s disease (AD) case-control 656 
status, AD-by-proxy phenotype and meta-analysis. 657 
 658 
Region   Case-control status (Phase 1)   AD-by-proxy (Phase 2)   Overall (Phase 3) 
Locus Chr Gene  SNP p  SNP p  SNP bp A1 A2 MAF Z p direction 
1 1 ADAMTS4  rs4575098 1.57E-04  rs4575098 6.88E-08  rs4575098 161155392 A G 0.240 6.36 2.05E-10 ?+++ 
2 1 CR1  rs6656401 1.39E-17  rs679515 8.85E-10  rs2093760 207786828 A G 0.205 8.82 1.10E-18 ++++ 
3 2 BIN1  rs4663105 3.58E-29  rs4663105 5.46E-26  rs4663105 127891427 C A 0.415 13.94 3.38E-44 ?+++ 
4 2 INPPD5  rs10933431 1.67E-06  rs10933431 2.51E-06  rs10933431 233981912 G C 0.235 -6.13 8.92E-10 ?--- 
5 3 HESX1  NA   rs184384746 1.24E-08  rs184384746 57226150 T C 0.002 5.69 1.24E-08 ???+ 
6 4 CLNK  rs6448453 0.024  rs6448451 1.19E-08  rs6448453 11026028 A G 0.252 6.00 1.93E-09 ?+-+ 
-- 4 HS3ST1  rs7657553 2.16E-08  rs7657553 0.790  rs7657553 11723235 A G 0.291 1.95 0.051 ?++- 
7 6 HLA-DRB1  rs9269853 2.66E-08  rs6931277 1.78E-07  rs6931277 32583357 T A 0.153 -6.49 8.41E-11 ?--- 
8 6 TREM2  NA   rs187370608 1.45E-16  rs187370608 40942196 A G 0.002 8.26 1.45E-16 ???+ 
9 6 CD2AP  rs9381563 5.35E-09  rs9381563 8.10E-06  rs9381563 47432637 C T 0.355 6.33 2.52E-10 ?+++ 
10 7 ZCWPW1  rs1859788 6.05E-09  rs7384878 2.38E-10  rs1859788 99971834 A G 0.310 -7.93 2.22E-15 ---- 
11 7 EPHA1  rs11763230 2.58E-11  rs7810606 1.01E-06  rs7810606 143108158 T C 0.500 -6.62 3.59E-11 ?--- 
12 7 CNTNAP2  NA   rs114360492 2.10E-09  rs114360492 145950029 T C 0.000 5.99 2.10E-09 ???+ 
13 8 CLU/PTK2B  rs4236673 6.36E-20  rs1532278 7.45E-09  rs4236673 27464929 A G 0.391 -8.98 2.61E-19 ---- 
14 10 ECHDC3  rs11257242 2.38E-08  rs11257238 5.84E-05  rs11257238 11717397 C T 0.375 5.69 1.26E-08 ?+++ 
15 11 MS4A6A  rs7935829 8.21E-13  rs1582763 4.72E-09  rs2081545 59958380 A C 0.381 -7.97 1.55E-15 ---- 
16 11 PICALM  rs10792832 1.12E-17  rs3844143 5.31E-11  rs867611 85776544 G A 0.314 -8.75 2.19E-18 ?--- 
17 11 SORL1  rs11218343 5.57E-11  rs11218343 2.81E-06  rs11218343 121435587 C T 0.040 -6.79 1.09E-11 ?--- 
18 14 SLC24A4  rs12590654 1.98E-08  rs12590654 3.70E-06  rs12590654 92938855 A G 0.344 -6.39 1.65E-10 ?--- 
19 15 ADAM10  rs442495 3.09E-04  rs442495 2.65E-07  rs442495 59022615 C T 0.320 -6.07 1.31E-09 ?--- 
20 15 APH1B  rs117618017 0.022  rs117618017 2.64E-07  rs117618017 63569902 T C 0.132 5.52 3.35E-08 ++++ 
21 16 KAT8  rs59735493 8.25E-04  rs59735493 3.72E-06  rs59735493 31133100 A G 0.300 -5.49 3.98E-08 ?--- 
22 17 SCIMP  rs113260531 3.21E-06  rs9916042 4.73E-08  rs113260531 5138980 A G 0.120 6.12 9.16E-10 ?+++ 





-- 17 BZRAP1-AS1  rs2632516 1.42E-09  rs2632516 0.005  rs2632516 56409089 C G 0.455 -4.90 9.66E-07 ?--- 
-- 18 SUZ12P1  rs8093731 4.63E-08  rs8093731 0.766  rs8093731 29088958 T C 0.010 -2.17 0.030 ?-?- 
24 18 ALPK2  rs76726049 0.039  rs76726049 1.83E-07  rs76726049 56189459 C T 0.014 5.52 3.30E-08 ?+++ 
25 19 ABCA7  rs4147929 8.64E-09  rs3752241 2.87E-08  rs111278892 1039323 G C 0.161 6.50 7.93E-11 ?+++ 
26 19 APOE  rs41289512 2.70E-194  rs75627662 9.51E-296  rs41289512 45351516 G C 0.039 35.50 5.79E-276 ?+++ 
27 19 AC074212.3  rs76320948 1.54E-05  rs76320948 1.80E-05  rs76320948 46241841 T C 0.046 5.46 4.64E-08 ?+?+ 
28 19 CD33  rs3865444 4.25E-08  rs3865444 4.97E-05  rs3865444 51727962 A C 0.320 -5.81 6.34E-09 ?--- 
29 20 CASS4   rs6014724 8.72E-08   rs6014724 6.32E-06   rs6014724 54998544 G A 0.089 -6.18 6.56E-10 ?--- 
Note: Independent lead SNPs are defined by r2 < .1; distinct genomic loci are >250kb apart. The locus column indicates the loci number based on Phase III 659 
(-- indicates that this locus is non-significant). The gene symbols are included to conveniently compare the significant loci with previously discovered loci. 660 
The bolded genes correspond to the novel loci indicating the genes in closest proximity to the most significant SNP, while emphasizing this is not necessarily 661 
the causal gene. Allele1 is the effect allele for the meta association statistic. The directions of effect of the distinct cohorts are in the following order: ADSP, 662 
IGAP, PGC-ALZ, UKB note that the first cohort is often missing as this concerns exome sequencing data. Corrected P value for significance = 5E-08 (marked 663 







Participants in this study were obtained from multiple sources, including raw data from case-667 
control samples collected by the Psychiatric Genomics Consortium (PGC-ALZ) and the Alzheimer’s 668 
Disease Sequencing Project (ADSP; made publicly available through dbGaP [see URLs]), summary 669 
data from the case-control samples in the International Genomics of Alzheimer’s Project (IGAP), 670 
and raw data from the population-based UK Biobank (UKB) sample which was used to create a 671 
weighted AD-proxy phenotype. An additional independent case-control sample (deCODE) was 672 
used for replication. Full descriptions of the samples and their respective phenotyping and 673 
genotyping procedures are provided in the Supplementary Note and the Life Sciences Reporting 674 
Summary.   675 
 676 
Data Analysis 677 
Single-marker association analysis 678 
Genome-wide association analysis (GWAS) for each of the ADSP, PGC-ALZ and UKB datasets was 679 
performed in PLINK47, using logistic regression for dichotomous phenotypes (cases versus 680 
controls for ADSP and PGC-ALZ cohorts), and linear regression for phenotypes analysed as 681 
continuous outcomes (proxy phenotype constructed as the number of parents with AD for UKB 682 
cohort). For the ADSP and PGC-ALZ cohorts, association tests were adjusted for gender, batch (if 683 
applicable), and the first 4 ancestry principal components. Twenty principal components were 684 
calculated, and depending on the dataset being tested, additional principal components (on top 685 





the PGC-ALZ cohorts age was included as a covariate. For 4,537 controls of the DemGene cohort 687 
(subset of PGC-ALZ), no detailed age information was available, besides the age range the 688 
subjects were in (20-45 years). We therefore set the age of these individuals conservatively to 20 689 
years. For the ADSP dataset, age was not included as a covariate due to the enrichment for older 690 
controls (mean age cases = 73.1 years (SE=7.8); mean age controls = 86.1 years (SE=4.5)) in their 691 
collection procedures. Correcting for age in ADSP would remove a substantial part of genuine 692 
association signals (e.g. well-established APOE locus rs11556505 is strongly associated to AD 693 
(P=1.08x10-99), which is lost when correcting for age (P=0.0054). For the UKB dataset, 12 ancestry 694 
principal components were included as covariates, as well as age, sex, genotyping array, and 695 
assessment centre. We used the genome-wide threshold for significance of P<5×10-8). 696 
 697 
Multivariate genome-wide meta-analysis 698 
Two meta-analyses were performed, including: phase 1) cohorts with case-control phenotypes 699 
(IGAP, ADSP and PGC-ALZ datasets), and phase 3) all cohorts, also including the UKB proxy 700 
phenotype. 701 
Because of partial overlap between cohorts, the per SNP test statistics was defined by 702 
𝑍𝑍𝑘𝑘 =
∑𝑖𝑖𝑤𝑤𝑖𝑖𝑍𝑍𝑖𝑖
�∑𝑖𝑖𝑤𝑤𝑖𝑖2 + ∑𝑖𝑖∑𝑗𝑗𝑤𝑤𝑖𝑖𝑤𝑤𝑗𝑗|𝐶𝐶𝐶𝐶𝐶𝐶𝑖𝑖𝑗𝑗|(𝑖𝑖 ≠ 𝑗𝑗)
 703 
where wi and Zi are the squared root of the sample size and the test statistics of SNP k in cohort 704 
i, respectively. CTI is the cross-trait LD score intercept estimated by LDSC14,48 using genome-wide 705 









where Ni and Nj are the sample sizes of cohorts i and j and Nsij the number of samples overlapping 708 
between them, and ρij the phenotypic correlation between the measures used in the two cohorts 709 
for the overlapping samples. Under the null hypothesis of no association any correlation between 710 
Zi and Zj is determined only by that phenotypic correlation, scaled by the relative degree of 711 
overlap. As such, this correlation can be estimated by the CTI.  712 
The test statistics per SNP per GWAS were converted from the P-value, incorporating the 713 
sign of either beta or odds ratio. When direction is aligned the conversion is two-sided. To avoid 714 
infinite values, we replaced P-value 1 with 0.999999 and P-value < 1e-323 to 1e-323 (the 715 
minimum >0 value in Python). The script for the multivariate GWAS is available online (see URLs). 716 
 717 
Effective sample size 718 
The effective sample size (Neff) is computed for each SNP k from the matrix M, containing the 719 
sample size Ni of each cohort i on the diagonal and the estimated number of shared data points 720 
Nsijρij = CTIij�𝑁𝑁𝑖𝑖𝑁𝑁𝑗𝑗  for each pair of cohorts i and j as the off-diagonal values. A recursive 721 
approach is used to compute Neff. Going from the first cohort to the last the (remaining) size of 722 
the current cohort is added to the total Neff. Then for each remaining other cohort it overlaps 723 
with, the size of those other cohorts is reduced by the expected number of samples shared by 724 
the current cohort; overlap between the remaining cohorts is similarly adjusted. This process 725 





The computation proceeds as follows. Starting with the first cohort in M, Neff is first 727 
increased by M1,1, corresponding to the sample size of that cohort. The proportion of samples 728 
shared between cohort 1 and each other cohort j is then computed as p1,j = M1,j/Mj,j, and M is 729 
adjusted to remove this overlap, multiplying all values in each column j by 1-p1,j. This amounts to 730 
reducing the sample size of each other cohort j by the number of samples it shares with cohort 1 731 
and reducing the shared samples between cohort j and subsequent cohorts by the same 732 
proportion. After this, the first row and column of M are discarded, and the same process is 733 
applied to the new M matrix. This is repeated until M is empty.  734 
The effective sample size is used as a parameter in the MAGMA analysis (Methods section 735 
1.14) and reported in the main text as the combined sample sizes for the meta-analysis. We use 736 
the term Nsum to indicate the total number of individuals when simply summing them over the 737 
distinct cohorts. The script for the Neff computation is available online (see URLs). 738 
 739 
Genomic risk loci definition 740 
We used FUMA26 v1.2.8, an online platform for functional mapping and annotation of genetic 741 
variants, to define genomic risk loci and obtain functional information of relevant SNPs in these 742 
loci. We first identified independent significant SNPs that have a genome-wide significant P-value 743 
(<5×10-8) and are independent from each other at r2<0.6. These SNPs were further represented 744 
by lead SNPs, which are a subset of the independent significant SNPs that are in approximate 745 
linkage equilibrium with each other at r2>0.6. We then defined associated genomic risk loci by 746 
merging any physically overlapping lead SNPs (LD blocks <250kb apart). LD information was 747 





For GWS SNPs in the defined risk loci, we applied a summary statistic-based fine-mapping model 749 
to identify credible causal SNPs within each locus, as previously described24. This Bayesian model 750 
estimates a per-SNP posterior probability of a true disease association using maximum likelihood 751 
estimation and the steepest descent approach, creating a set of SNPs in each locus that contains 752 
the causal SNP in 99% of cases, given that the causal variants are among the genotyped/imputed 753 
SNPs. The software used, FM-summary, is available online (see URLs). 754 
 755 
Independent sample replication  756 
For novel SNPs identified in the phase 3 meta-analysis, replication was tested in the independent 757 
deCODE sample using logistic regression with Alzheimer’s disease status as the response and 758 
genotype counts and a set of nuisance variables including sex, county of birth, and current age 759 
as predictors.20 Correction for inflation of test statistics due to relatedness and population 760 
stratification in this Icelandic cohort was performed using the intercept estimate (1.29) from LD 761 
score regression14. 762 
 763 
Conditional analysis 764 
We performed conditional analysis with GCTA-COJO49 to assess the independence of association 765 
signals, either within or between GWAS risk loci. COJO enables conditional analysis of GWAS 766 
summary statistics without individual-level genotype data. We therefore performed conditional 767 
analysis on the phase 3 summary statistics, using 10,000 randomly selected unrelated samples 768 
from the UKB dataset as a reference dataset to determine LD-patterns. Conditional analysis was 769 






Heritability and Genetic Correlation 772 
LD score regression14 was used to estimate clinical AD heritability and to calculate genetic 773 
correlations48 between the case-control and proxy phenotypes using summary statistics. Pre-774 
calculated LD scores from the 1000 Genomes European reference population were obtained 775 
online (see URLs). Liability heritability was calculated with a population prevalence of 0.0431 (the 776 
population prevalence of age group 70-75 in the Western European population, resembling the 777 
average age of onset of 74.5 for the clinical case group) and a sample prevalence of 0.304. The 778 
genetic correlation was calculated on HapMap3 SNPs only to ensure high quality LD score 779 
calculation. 780 
 781 
Stratified Heritability 782 
To test whether specific categories of SNP annotations were enriched for heritability, we 783 
partitioned the SNP heritability for binary annotations using stratified LD score regression14. 784 
Heritability enrichment was calculated as the proportion of heritability explained by a SNP 785 
category divided by the proportion of SNPs that are in that category. Partitioned heritability was 786 
computed by 28 functional annotation categories, by minor allele frequency (MAF) in six 787 
percentile bins, and by 22 chromosomes. Annotations for binary categories of functional genomic 788 
characteristics (e.g. coding or regulatory regions) were obtained online (see URLs). The 789 
Bonferroni-corrected significance threshold for 56 annotations was set at: P<0.05/56=8.93×10−4. 790 
 791 





We calculated polygenic scores (PGS) using two independent genotype datasets. First, 761 793 
individuals (379 cases and 382 controls) from the ADDNeuroMed study50 were included, using 794 
the same QC and imputation approach as for the other datasets with genotype-level data (see 795 
Supplementary Note). Second, 1459 individuals (912 severe, late-stage cases and 547 age-796 
matched controls with little to no cognitive dysfunction) from the TGEN study22 were assessed 797 
and their diagnostic status was confirmed via post-mortem neuropathology. Imputed SNPs in this 798 
sample were filtered based on INFO>0.9 and MAF>0.01. PGS were created using PLINK47 for the 799 
TGEN dataset and PRSice21 for the ADDNeuroMed dataset. In both samples, PGS were calculated 800 
on hard-called imputed genotypes using P-value thresholds from 0.0 to 0.5 and using PLINK’s 801 
clumping procedure to prune for LD. Clumping was based on the effect size estimates of SNPs 802 
originating from the Phase 3 meta-analysis for the ADDNeuroMed sample. For TGEN, clumping 803 
was previously performed using the IGAP summary statistics; these clumped SNPs were filtered 804 
for overlap with the Phase 3 SNPs. PGS were calculated in both samples using the SNP effect size 805 
estimates from the Phase 3 meta-analysis. The explained variance (ΔR2) was derived from a linear 806 
model in which the AD phenotype was regressed on each PGS while controlling for GWAS 807 
covariates, compared to a linear model with covariates only. In the TGEN dataset, sensitivity, 808 
specificity, and area under the curve (AUC) of predicting confirmed case/control status were 809 
calculated, using the R package pROC51 and bootstrapped confidence intervals. Of note, 810 
approximately 3% of the TGEN sample overlapped with the IGAP cohort included in the meta-811 
analysis; previous simulation work using PGS in this sample has shown that this overfitting leads 812 






Functional Annotation 815 
Functional annotation of GWS SNPs implicated in the meta-analysis was performed using FUMA26 816 
v1.2.8. Functional consequences for these SNPs were obtained by matching SNPs to databases 817 
containing known functional annotations, including ANNOVAR52 categories, Combined 818 
Annotation Dependent Depletion (CADD) scores23, RegulomeDB53 (RDB) scores, and chromatin 819 
states54,55. ANNOVAR annotates the functional consequence of SNPs on genes (e.g. intron, exon, 820 
intergenic). CADD scores predict how deleterious the effect of a SNP with higher scores referring 821 
to higher deleteriousness. A CADD score above 12.37 is the threshold to be potentially 822 
pathogenic56. The RegulomeDB score is a categorical score based on information from expression 823 
quantitative trait loci (eQTLs) and chromatin marks, ranging from 1a to 7 with lower scores 824 
indicating an increased likelihood of having a regulatory function. The chromatin state represents 825 
the accessibility of genomic regions (every 200bp) with 15 categorical states predicted by a 826 
hidden Markov model based on 5 chromatin marks in the Roadmap Epigenomics Project.55 A 827 
lower state indicates higher accessibility, with states 1-7 referring to open chromatin states. We 828 
annotated the minimum chromatin state across tissues to SNPs. A legend describing the 829 
RegulomeDB and chromatin state scores can be found in the Supplementary Note. 830 
 831 
Gene-mapping 832 






1. Positional mapping maps SNPs to genes based on physical distance (within a 10kb 835 
window) from known protein coding genes in the human reference assembly 836 
(GRCh37/hg19).  837 
2. eQTL mapping maps SNPs to genes with which they show a significant eQTL association 838 
(i.e. allelic variation at the SNP is associated with the expression level of that gene). eQTL 839 
mapping uses information from 45 tissue types in 3 data repositories (GTEx57 v6, Blood 840 
eQTL browser58, BIOS QTL browser59), and is based on cis-eQTLs which can map SNPs to 841 
genes up to 1Mb apart. We used a false discovery rate (FDR) of 0.05 to define significant 842 
eQTL associations. 843 
3. Chromatin interaction mapping was performed to map SNPs to genes when there is a 844 
three-dimensional DNA-DNA interaction between the SNP region and another gene 845 
region. Chromatin interaction mapping can involve long-range interactions as it does not 846 
have a distance boundary. FUMA currently contains Hi-C data of 14 tissue types from the 847 
study of Schmitt et al60. Since chromatin interactions are often defined in a certain 848 
resolution, such as 40kb, an interacting region can span multiple genes. If a SNP is located 849 
in a region that interacts with a region containing multiple genes, it will be mapped to 850 
each of those genes. To further prioritize candidate genes, we selected only genes 851 
mapped by chromatin interaction in which one region involved in the interaction overlaps 852 
with a predicted enhancer region in any of the 111 tissue/cell types from the Roadmap 853 
Epigenomics Project55 and the other region is located in a gene promoter region (250bp 854 
up and 500bp downstream of the transcription start site and also predicted by Roadmap 855 





increases the likelihood that those identified will have a plausible biological function. We 857 
used an FDR of 1×10-5 to define significant interactions, based on previous 858 
recommendations60 modified to account for the differences in cell lines used here. 859 
 860 
Brain-specific QTL annotation 861 
As AD is characterized by neurodegeneration, we annotated the significant genomic loci with 862 
publicly available databases of expression, methylation, and histone acetylation QTLs, as 863 
catalogued in BRAINEAC61, CommonMind Consortium Portal62 and xQTL Serve63, as an extension 864 
of the GTEx tissue eQTL mapping performed in FUMA. Descriptions of these brain eQTL databases 865 
and settings we used are in the Supplementary Note.  866 
   867 
 868 
Gene-based analysis 869 
To account for the distinct types of genetic data in this study, genotype array (PGC-ALZ, IGAP, 870 
UKB) and whole-exome sequencing data (ADSP), we first performed two gene-based genome-871 
wide association analysis (GWGAS) using MAGMA32, followed by a meta-analysis. SNP-based P-872 
values from the meta-analysis of the 3 genotype-array-based datasets were used as input for the 873 
first GWGAS, while the unimputed individual-level sequence data of ADSP was used as input for 874 
the second GWGAS. 18,233 protein-coding genes (each containing at least one SNP in the GWAS) 875 
from the NCBI 37.3 gene definitions were used as basis for GWGAS in MAGMA. Bonferroni 876 






Gene-set analysis 879 
Results from the GWGAS analyses were used to test for association in 7,086 predefined gene-880 
sets of four categories: 881 
1. 6,994 curated gene-sets representing known biological and metabolic pathways derived 882 
from Gene Ontology (5917 gene-sets), Biocarta (217 gene-sets), KEGG (186 gene-sets), 883 
Reactome (674 gene-sets) catalogued by and obtained from the MsigDB version 6.164 (see 884 
URLs) 885 
2. Gene expression values from 53 tissues obtained from GTEx57, log2 transformed with 886 
pseudocount 1 after winsorization at 50 and averaged per tissue. 887 
3. Cell-type specific expression in 24 broad categories of brain cell types, which were 888 
calculated following the method described in 37. Briefly, brain cell-type expression data 889 
was drawn from single-cell RNA sequencing data from mouse brains. For each gene, the 890 
value for each cell-type was calculated by dividing the mean Unique Molecular Identifier 891 
(UMI) counts for the given cell type by the summed mean UMI counts across all cell types. 892 
Single-cell gene-sets were derived by grouping genes into 40 equal bins based on 893 
specificity of expression. 894 
4. Nucleus specific gene expression of 15 distinct human brain cell-types from the study 895 
described in65. The value for each cell-type was calculated as in point 3. 896 
These gene-sets were tested using MAGMA. We computed competitive P-values, which 897 
represent the test of association for a specific gene-set compared with genes not in the gene-set 898 
to correct for baseline level of genetic association in the data. The Bonferroni-corrected 899 





was defined by the number of tests within the category. Conditional analyses were performed as 901 
a follow-up using MAGMA to test whether each significant association observed was 902 
independent of APOE (a gene-set including all genes within region chr19:45,020,859-45,844,508). 903 
Furthermore, the association between each of the significant gene-sets was tested conditional 904 
on each of the other significantly associated gene-sets. Gene-sets that retained their association 905 
after correcting for other sets were considered to represent independent signals. We note that 906 
this is not a test of association per se, but rather a strategy to identify, among gene-sets with 907 
known significant associations and overlap in genes, which set(s) are responsible for driving the 908 
observed association. 909 
 910 
Cross-Trait Genetic Correlation 911 
Genetic correlations (rg) between AD and 41 phenotypes were computed using LD score 912 
regression14, based on GWAS summary statistics obtained from publicly available databases (see 913 
URLs and Supplementary Table 26). The Bonferroni-corrected significance threshold was 0.05/41 914 
traits=1.22×10-3. 915 
 916 
Mendelian Randomisation 917 
To infer credible causal associations between AD and traits that are genetically correlated with 918 
AD, we performed Generalised Summary-data based Mendelian Randomisation36 (GSMR; see 919 
URLs). This method utilizes summary-level data to test for putative causal associations between 920 
a risk factor (exposure) and an outcome by using independent genome-wide significant SNPs as 921 





genetic instruments that showed clear pleiotropic effects on the exposure phenotype and the 923 
outcome phenotype. We used a threshold p-value of 0.01 for the outlier detection analysis in 924 
HEIDI, which removes 1% of SNPs by chance if there is no pleiotropic effect. To test for a potential 925 
causal effect of various outcomes on risk for AD, we selected phenotypes in non-overlapping 926 
samples that showed (suggestive) significant (P<0.05) genetic correlations (rg) with AD. With this 927 
method it is typical to test for bi-directional causation by repeating the analyses while switching 928 
the role of the exposure and the outcome; however, because AD is a late-onset disease, it makes 929 
little sense to estimate its causal effect on outcomes that develop earlier in life, particularly when 930 
the summary statistics for these outcomes were derived mostly from younger samples than those 931 
of AD cases. Therefore, we conducted these analyses only in one direction. For genetically 932 
correlated phenotypes, we selected independent (r2=<0.1), GWS lead SNPs as instrumental 933 
variables in the analyses. The method estimates a putative causal effect of the exposure on the 934 
outcome (bxy) as a function of the relationship between the SNPs’ effects on the exposure (bzx) 935 
and the SNPs’ effects on the outcome (bzy), given the assumption that the effect of non-936 
pleiotropic SNPs on an exposure (x) should be related to their effect on the outcome (y) in an 937 
independent sample only via mediation through the phenotypic causal pathway (bxy). The 938 
estimated causal effect coefficients (bxy) are approximately equal to the natural log odds ratio 939 
(OR)36 for a case-control trait. An OR of 2 can be interpreted as a doubled risk compared to the 940 
population prevalence of a binary trait for every SD increase in the exposure trait. This method 941 
can help differentiate the causal direction of association between two traits, but cannot make 942 





Data Availability Statement 944 
Summary statistics will be made available for download upon publication (https://ctg.cncr.nl).  945 
 946 
Code Availability Statement 947 
The analyses were produced with standard code for software programs utilized, which can be 948 
made available on request from the first author. All software used is freely available online. 949 
Custom code for the meta-analysis correcting for overlapping samples is available at 950 
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